Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Real-World Evidence for Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients

Jeries Kort, James J Ignatz-Hoover, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 3773.

https://doi.org/10.1182/blood-2024-210334

Published: 2024

Journal Articles

PSMC2 Overexpression Promotes Synthetic Lethality Sensitizing Multiple Myeloma Cells to p97 Inhibition

James J Ignatz-Hoover, Pryianka Rana, John D'Cruz, E Ricky Chan, Ehsan Malek, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2024-211260

Published: 2024

Journal Articles

Disparity in Access to Myeloma CAR-T: A Geospatial Analysis of Distance to CAR-T Centers and Its Impact on Mortality

Michael Daunov, Benjamin Gorham, James J Ignatz-Hoover

Blood (2024) 144 (Supplement 1): 2409.

https://doi.org/10.1182/blood-2024-212286

Published: 2024

Journal Articles

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

Nikki Agarwal, Pingfu Fu, Michael Daunov, Brenda W Cooper, Ben K. Tomlinson, Rebecca B. Klisovic, Marcos de Lima, Folashade Otegbeye, Changchun Deng, Yeritza Hernandez-Collazo, Jignesh Dalal, James Martin, Seunghee Margevicius, James J. Ignatz-Hoover, Ok-Kyong Chaekal, Molly Megan Gallogly, Koen van Besien, Leland Metheny

Blood (2024) 144 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2024-210550

Published: 2024

Journal Articles

A Novel Immunoproteasome Activator That Expands and Amplifies the Multiple Myeloma Immunopeptidome and Promotes Cytotoxic T-Cell Activity

James J. Driscoll, II, Ehsan Malek, Priyanka S. Rana, James J Ignatz-Hoover

Blood (2024) 144 (Supplement 1): 6832.

https://doi.org/10.1182/blood-2024-211485

Published: 2024

Journal Articles

The TGFβ Type I Receptor Kinase Inhibitor Vactosertib Improves T-Cell Fitness in Relapsed/Refractory Multiple Myeloma: A Phase 1b Trial

Ehsan Malek, James J Ignatz-Hoover, Priyanka S. Rana, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 7042.

https://doi.org/10.1182/blood-2024-211233

Published: 2024

Journal Articles

Vactosertib, a Novel TGFb Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness:a Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple Myeloma

Ehsan Malek, Priyanka S. Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy, James J. Ignatz-Hoover, Leland Metheny, Seong-Jin Kim, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 4749.

https://doi.org/10.1182/blood-2023-172711

Published: 2023

Journal Articles

An Immunoproteasome Activator That Increases MHC Class I Antigen Presentation to Enhance Anti-Tumor Immunity

James J. Driscoll, II, Priyanka S. Rana, Ehsan Malek, James J. Ignatz-Hoover

Blood (2023) 142 (Supplement 1): 3642.

https://doi.org/10.1182/blood-2023-189541

Published: 2023

Journal Articles

HDAC6 Inhibition Activates Proteasomes to Modulate the MHC Class I Immunopeptidome and Promote Antimyeloma Immunity

Priyanka S. Rana, James J. Ignatz-Hoover, Ehsan Malek, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 6586.

https://doi.org/10.1182/blood-2023-189262

Published: 2023

Journal Articles

PSMC2 Overexpression Enhances Proteasome Activity, Mitigates ER Stress, and Correleates with Reduced Overall Survival in Multiple Myeloma

James J. Ignatz-Hoover, E Ricky Chan, Jack D'Cruz, Pryianka Rana, Ehsan Malek, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 6617.

https://doi.org/10.1182/blood-2023-190462

Published: 2023

Journal Articles

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

Abhishek Maiti, Muharrem Muftuoglu, James J. Ignatz-Hoover, Courtney D. DiNardo, Farhad Ravandi, Michael Andreeff, Lianchun Xiao, Xuelin Huang, Keyur P. Patel, Jason B Litten, Eliot Bourk, Stephanie Astrow, Hagop M. Kantarjian, Ben K. Tomlinson, Naval Daver, David Wald

Blood (2023) 142 (Supplement 1): 4863.

https://doi.org/10.1182/blood-2023-182885

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Real-World Evidence for Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients

PSMC2 Overexpression Promotes Synthetic Lethality Sensitizing Multiple Myeloma Cells to p97 Inhibition

Disparity in Access to Myeloma CAR-T: A Geospatial Analysis of Distance to CAR-T Centers and Its Impact on Mortality

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

A Novel Immunoproteasome Activator That Expands and Amplifies the Multiple Myeloma Immunopeptidome and Promotes Cytotoxic T-Cell Activity

The TGFβ Type I Receptor Kinase Inhibitor Vactosertib Improves T-Cell Fitness in Relapsed/Refractory Multiple Myeloma: A Phase 1b Trial

Vactosertib, a Novel TGFb Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness:a Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple Myeloma

An Immunoproteasome Activator That Increases MHC Class I Antigen Presentation to Enhance Anti-Tumor Immunity

HDAC6 Inhibition Activates Proteasomes to Modulate the MHC Class I Immunopeptidome and Promote Antimyeloma Immunity

PSMC2 Overexpression Enhances Proteasome Activity, Mitigates ER Stress, and Correleates with Reduced Overall Survival in Multiple Myeloma

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only